Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

/PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic...

Related Keywords

Japan ,United States ,Greg Mayes ,Craig Gordon ,Amzak Health ,Venture Fund ,Capital Group ,Antios Therapeutics Inc ,Antios Therapeutics ,Active Site Polymerase Inhibitor Nucleotide ,Chief Executive Officer ,Avego Bioscience Capital ,Heartland Healthcare ,Delos Capital ,Lumira Ventures ,Domain Partners ,Sixty Degree Capital ,Soleus Capital ,Aisling Capital ,Granite Point Capital Management ,Lifesci Venture Partners ,Antios Board ,Antios Therapeutic ,Sustained Anti Viral Efficacy ,